Patient-reported outcomes in moderate-to-severe allergic asthmatics treated with omalizumab: a systematic literature review of randomized controlled trials

Jonathan CorrenDavid Geffen School of Medicine at UCLA, Los Angeles, CA, USA;

Abhishek KavatiNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA;

Benjamin OrtizNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA;

Ashok VegesnaNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA;

Jennifer A. ColbyXcenda, LLC, Palm Harbor, FL, USA;

Kimberly RuizXcenda, LLC, Palm Harbor, FL, USA; Correspondence[email protected]

Reynold A. Panettieri JrRutgers, The State University of New Jersey, Rutgers Institute for Translational Medicine and Science, New Brunswick, NJ, USA

show all

Citations (6)

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Sheila Cabrejos, Ana Moreira, Andreina Ramirez, Santiago Quirce, Gregorio Soto Campos, Ignacio Dávila & Paloma Campo. (2020) FENOMA Study: Achieving Full Control in Patients with Severe Allergic Asthma. Journal of Asthma and Allergy 13, pages 159-166.
Read now

Alicia Padilla Galo, Marina Labor, Angelica Tiotiu, Ilaria Baiardini, Nicola Scichilone & Fulvio Braido. (2018) Impact of reslizumab on outcomes of severe asthmatic patients: current perspectives. Patient Related Outcome Measures 9, pages 267-273.
Read now

Articles from other publishers (4)

Ioana Agache, Jessica Beltran, Cezmi Akdis, Mubeccel Akdis, Carlos Canelo‐Aybar, Giorgio Walter Canonica, Thomas Casale, Tomas Chivato, Jonathan Corren, Stefano Del Giacco, Thomas Eiwegger, Davide Firinu, James E. Gern, Eckard Hamelmann, Nicola Hanania, Mika Mäkelä, Irene Hernández‐Martín, Parameswaran Nair, Liam O'Mahony, Nikolaos G. Papadopoulos, Alberto Papi, Hae‐Sim Park, Luis Pérez de Llano, Margarita Posso, Claudio Rocha, Santiago Quirce, Joaquin Sastre, Mohamed Shamji, Yang Song, Corinna Steiner, Jurgen Schwarze, Pablo Alonso‐Coello, Oscar Palomares & Marek Jutel. (2020) Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthma. Allergy 75:5, pages 1023-1042.
Crossref

Delia Colombo, Emanuela Zagni, Fabio Ferri & Giorgio Walter Canonica. (2019) Gender differences in asthma perception and its impact on quality of life: a post hoc analysis of the PROXIMA (Patient Reported Outcomes and Xolair® In the Management of Asthma) study. Allergy, Asthma & Clinical Immunology 15:1.
Crossref

Omer Qibi, Severine Audusseau, Andrea Mogas, Zoulfia Allakhverdi, Abdelilah Soussi Gounni, Saba Al Heialy & Qutayba Hamid. (2018) No evidence for IgE receptor FcεRI expression on bronchial epithelial cells of asthmatic patients. AIMS Allergy and Immunology 2:4, pages 165-179.
Crossref

Giorgio Walter Canonica, Paola Rottoli, Caterina Bucca, Maria Cristina Zappa, Giovanni Michetti, Bruno Macciocchi, Cristiano Caruso, Pierachille Santus, Marta Bartezaghi & Laura Rigoni. (2018) Improvement of patient-reported outcomes in severe allergic asthma by omalizumab treatment: the real life observational PROXIMA study. World Allergy Organization Journal 11, pages 33.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Patient-reported outcomes in moderate-to-severe allergic asthmatics treated with omalizumab: a systematic literature review of randomized controlled trials

Articles from other publishers (4)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Patient-reported outcomes in moderate-to-severe allergic asthmatics treated with omalizumab: a systematic literature review of randomized controlled trials

Citations (6)

Read on this site (2)

Articles from other publishers (4)

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date